Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.44 |
| ▸ | LPL | P06858 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382334 | 0.90 | PDE4B (0.48) | LIPGLPLPDE4BHIF1AKDM4E | |
| SCHEMBL1669436 | 0.85 | LIPG (0.47) | LIPGLPLHIF1AALDH1A1HPGD | |
| SCHEMBL17822801 | 0.82 | DGAT1 (0.41) | LIPGLPLHIF1AKDM4EALDH1A1 | |
| SCHEMBL25035049 | 0.79 | HIF1A (0.43) | LIPGLPLHIF1AKDM4EALDH1A1 | |
| SCHEMBL17798424 | 0.79 | ALPL (0.45) | PDE4BKDM4EALDH1A1NPSR1MAPT | |
| SCHEMBL20074527 | 0.78 | LMNA (0.43) | HIF1AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL29727178 | 0.78 | LMNA (0.43) | HIF1AKDM4EMAPTMEN1KMT2A | |
| SCHEMBL2281668 | 0.77 | ALDH1A1 (0.51) | LIPGLPLHIF1AKDM4EALDH1A1 | |
| SCHEMBL2697552 | 0.77 | CA1 (0.53) | LIPGLPLHIF1ADGAT1EGFR | |
| SCHEMBL31258763 | 0.77 | CA1 (0.53) | LIPGLPLHIF1ADGAT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2024-02-22 | — | — | US | disclosed |
| CN-109963870-B | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116284404-A | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116173232-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116059394-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059201-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CORNELL UNIVERSITY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2014-06-12 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012154213-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LIPG 2389/4885LPL 4725/4885MTNR1A 3522/4885 |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | MYOF, FTH1, HCCS | LIPG 3252/4885LPL 4490/4885MTNR1A 964/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LIPG 2389/4885LPL 4725/4885MTNR1A 3522/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | LIPG 1882/4885LPL 2765/4885MTNR1A 3805/4885 |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | TNFSF11, CD14, TNFRSF1A | LIPG 2627/4885LPL 4669/4885MTNR1A 1719/4885 |
| US-20140194383-A1 | MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | CALCOCO2, MDN1, MBNL1 | LIPG 3389/4885LPL 4591/4885MTNR1A 3123/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | LIPG 651/4885LPL 2364/4885MTNR1A 4635/4885 |
| US-20240058450-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | LIPG 651/4885LPL 2364/4885MTNR1A 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.